Market Watch August 9, 2012 12:06 P.M. EDT
The company added that it has also made "significant progress" in attaining expanded patent protection for Vascepa in the U.S. and Europe. Amarin hopes to launch Vascepa early in the first quarter 2013 and is considering taking on a marketing partner for the endeavor.
that says it all right there. Going to $14 on Friday.
might as well say it's approved..lol
like it.
nicce
The meaning of which is they don't have patents -yet
fact gents facts
wishing is bs
sure sounds approved.
on way to $30's.
there you go..on to $30's.
There you go..wouldn't say that if not approved.